Patents by Inventor David A. Dickason

David A. Dickason has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR TREATING ACNE
    Publication number: 20220331269
    Abstract: A topical pharmaceutical composition comprising a solution of 2-(2-ethoxyethoxy)ethanol in a first solvent that is a 2-(2-ethoxyethoxy)ethanol solvent.
    Type: Application
    Filed: July 1, 2022
    Publication date: October 20, 2022
    Inventors: Eugene R. Cooper, Matthew Callahan, Michael Thurn, David Dickason
  • SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS
    Publication number: 20220000830
    Abstract: The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.
    Type: Application
    Filed: July 12, 2021
    Publication date: January 6, 2022
    Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: James T. Dalton, Thomas G. BIRD, Tai AHN, David A. DICKASON, Seoung-Soo HONG
  • Solid forms of selective androgen receptor modulators
    Patent number: 11090283
    Abstract: The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: August 17, 2021
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: James T. Dalton, Thomas G. Bird, Tai Ahn, David A. Dickason, Seoung-Soo Hong
  • COMPOSITIONS FOR TREATING ACNE
    Publication number: 20200022927
    Abstract: A topical pharmaceutical composition comprising a solution of 2-(2-ethoxyethoxy)ethanol in a first solvent that is a 2-(2-ethoxyethoxy)ethanol solvent.
    Type: Application
    Filed: February 14, 2018
    Publication date: January 23, 2020
    Inventors: Eugene R. Cooper, Matthew Callahan, Michael Thurn, David Dickason
  • Polymorphic forms of naltrexone
    Patent number: 10328070
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: June 25, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Polymorphic Forms of Naltrexone
    Publication number: 20190167664
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: November 27, 2018
    Publication date: June 6, 2019
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Polymorphic forms of naltrexone
    Patent number: 10166228
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: January 1, 2019
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • POLYMORPHIC FORMS OF NALTREXONE
    Publication number: 20180303825
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: April 24, 2018
    Publication date: October 25, 2018
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Polymorphic forms of naltrexone
    Patent number: 9980958
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: May 29, 2018
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Polymorphic Forms of Naltrexone
    Publication number: 20180110773
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: October 26, 2017
    Publication date: April 26, 2018
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Polymorphic forms of naltrexone
    Patent number: 9827240
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 28, 2017
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS
    Publication number: 20170266149
    Abstract: The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.
    Type: Application
    Filed: November 24, 2016
    Publication date: September 21, 2017
    Applicant: GTx, Inc.
    Inventors: James T. DALTON, Thomas G. BIRD, Tai AHN, David A. DICKASON, Seoung-Soo HONG
  • Polymorphic Forms of Naltrexone
    Publication number: 20170209430
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: December 16, 2016
    Publication date: July 27, 2017
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Polymorphic forms of naltrexone
    Patent number: 9556189
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: January 31, 2017
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • POLYMORPHIC FORMS OF NALTREXONE
    Publication number: 20160362415
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: June 7, 2016
    Publication date: December 15, 2016
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Polymorphic forms of naltrexone
    Patent number: 9365580
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: June 14, 2016
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Polymorphic Forms of Naltrexone
    Publication number: 20160137657
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Application
    Filed: November 19, 2015
    Publication date: May 19, 2016
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS
    Publication number: 20160128969
    Abstract: The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.
    Type: Application
    Filed: October 5, 2015
    Publication date: May 12, 2016
    Inventors: James T. DALTON, Thomas G. BIRD, Tai AHN, David A. DICKASON, Seoung-Soo HONG
  • Polymorphic forms of naltrexone
    Patent number: 9221830
    Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: December 29, 2015
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
  • Solid forms of selective androgen receptor modulators
    Patent number: 9150501
    Abstract: The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: October 6, 2015
    Assignee: GTx, Inc.
    Inventors: James T. Dalton, Thomas G. Bird, Tai Ahn, David A. Dickason, Seoung-Soo Hong